Comprehensive Evaluation of Clinical Efficacy and Safety of Celecoxib Combined with Chemotherapy in Management of Gastric Cancer

The study evaluated the efficacy and safety of combining celecoxib with chemotherapy in treating gastric cancer, involving 230 patients. Results showed no significant difference in 3-year overall survival (OS) and disease-free survival (DFS) between the experimental and control groups overall. However, patients with positive COX-2 expression had significantly better outcomes with celecoxib, with a 3-year OS of 78% and DFS of 70%. Quality of life improvements were noted in the celecoxib group, and adverse events were similar between groups, indicating the combination treatment was relatively safe. The study suggested celecoxib could be particularly beneficial for COX-2 positive gastric cancer patients, though further large-scale studies were needed for validation.